SCHEMBL6285469

SCHEMBL6285469

COc1ccc(Cl)cc1S(=O)(=O)n1cc(/C(C)=N\NC(=N)N)c2ccccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.47
▸ POLB P06746 3/20 0.47
▸ TP53 P04637 1/20 0.47
▸ HTR6 P50406 6/20 0.40
▸ CPT1A P50416 3/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ HTR2A P28223 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ TSHR P16473 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ MAPT P10636 2/20 0.38
▸ CPT1B Q92523 2/20 0.37
▸ CPT2 P23786 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ KAT6A Q92794 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6285474 1.00 ALDH1A1 (0.47) ALDH1A1POLBTP53HTR6CPT1A
SCHEMBL6283014 0.89 LMNA (0.39) ALDH1A1HTR6MEN1KMT2ASMN1; SMN2
SCHEMBL6283012 0.89 LMNA (0.39) ALDH1A1HTR6MEN1KMT2ASMN1; SMN2
SCHEMBL6285576 0.85 HTR6 (0.55) POLBHTR6MEN1KMT2ASMN1; SMN2
SCHEMBL6285571 0.85 HTR6 (0.55) POLBHTR6MEN1KMT2ASMN1; SMN2
SCHEMBL6286990 0.83 HTR6 (0.45) ALDH1A1TP53HTR6MEN1KMT2A
SCHEMBL6286983 0.83 HTR6 (0.45) ALDH1A1TP53HTR6MEN1KMT2A
SCHEMBL6287695 0.81 FABP4 (0.40) ALDH1A1HTR6MEN1KMT2ARAB9A
SCHEMBL6287691 0.81 FABP4 (0.40) ALDH1A1HTR6MEN1KMT2ARAB9A
SCHEMBL6287560 0.80 HTR6 (0.46) HTR6MEN1KMT2AHTR2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 — — US claimed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 — — US claimed
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 — — US disclosed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR2A ALDH1A1 757/4885POLB 4700/4885TP53 4817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback